408 related articles for article (PubMed ID: 32476780)
21. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma.
Wang Z; He L; Li W; Xu C; Zhang J; Wang D; Dou K; Zhuang R; Jin B; Zhang W; Hao Q; Zhang K; Zhang W; Wang S; Gao Y; Gu J; Shang L; Tan Z; Su H; Zhang Y; Zhang C; Li M
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34489334
[TBL] [Abstract][Full Text] [Related]
22. Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Tao Z; Ruan H; Sun L; Kuang D; Song Y; Wang Q; Wang T; Hao Y; Chen K
Cancer Immunol Res; 2019 Jul; 7(7):1135-1147. PubMed ID: 31113805
[TBL] [Abstract][Full Text] [Related]
23. UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2.
Bai DS; Wu C; Yang LX; Zhang C; Zhang PF; He YZ; Cai JB; Song ZJ; Dong ZR; Huang XY; Ke AW; Shi GM
Oncotarget; 2016 May; 7(22):32946-55. PubMed ID: 27121050
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of Tumor-Infiltrating CD49a
Sun H; Liu L; Huang Q; Liu H; Huang M; Wang J; Wen H; Lin R; Qu K; Li K; Wei H; Xiao W; Sun R; Tian Z; Sun C
Cancer Immunol Res; 2019 Sep; 7(9):1535-1546. PubMed ID: 31311791
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal Stem Cells Promote Hepatocarcinogenesis via lncRNA-MUF Interaction with ANXA2 and miR-34a.
Yan X; Zhang D; Wu W; Wu S; Qian J; Hao Y; Yan F; Zhu P; Wu J; Huang G; Huang Y; Luo J; Liu X; Liu B; Chen X; Du Y; Chen R; Fan Z
Cancer Res; 2017 Dec; 77(23):6704-6716. PubMed ID: 28947421
[TBL] [Abstract][Full Text] [Related]
26. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
27. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.
El-Abd N; Fawzy A; Elbaz T; Hamdy S
Tumour Biol; 2016 Jan; 37(1):211-6. PubMed ID: 26189841
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
30. PIGU promotes hepatocellular carcinoma progression through activating NF-κB pathway and increasing immune escape.
Wei X; Yang W; Zhang F; Cheng F; Rao J; Lu L
Life Sci; 2020 Nov; 260():118476. PubMed ID: 32971102
[TBL] [Abstract][Full Text] [Related]
31. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
32. Long non-coding RNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma by targeting miR‑206.
Chang Y; Zhang J; Zhou C; Qiu G; Wang G; Wang S; Chang X; Li X; Fan L
Oncol Rep; 2018 Dec; 40(6):3625-3634. PubMed ID: 30272362
[TBL] [Abstract][Full Text] [Related]
33. Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis.
Atanasov G; Dino K; Schierle K; Dietel C; Aust G; Pratschke J; Seehofer D; Schmelzle M; Hau HM
World J Surg Oncol; 2019 Dec; 17(1):217. PubMed ID: 31830991
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method.
Ji NY; Park MY; Kang YH; Lee CI; Kim DG; Yeom YI; Jang YJ; Myung PK; Kim JW; Lee HG; Kim JW; Lee K; Song EY
Int J Mol Med; 2009 Dec; 24(6):765-71. PubMed ID: 19885616
[TBL] [Abstract][Full Text] [Related]
35. FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
Liu ZY; Lin XT; Zhang YJ; Gu YP; Yu HQ; Fang L; Li CM; Wu D; Zhang LD; Xie CM
Cancer Lett; 2023 Jul; 566():216257. PubMed ID: 37277019
[TBL] [Abstract][Full Text] [Related]
36. Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems (Review).
Li X; Gu B; Wang B; Feng Z; Ma Y; Li H; Lucas A; Chen H
Oncol Rep; 2020 Dec; 44(6):2345-2352. PubMed ID: 33125140
[TBL] [Abstract][Full Text] [Related]
37. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer.
O'Rourke JM; Sagar VM; Shah T; Shetty S
World J Gastroenterol; 2018 Oct; 24(39):4436-4447. PubMed ID: 30357021
[TBL] [Abstract][Full Text] [Related]
38. Neutrophils: Driving inflammation during the development of hepatocellular carcinoma.
Chen H; Zhou XH; Li JR; Zheng TH; Yao FB; Gao B; Xue TC
Cancer Lett; 2021 Dec; 522():22-31. PubMed ID: 34517084
[TBL] [Abstract][Full Text] [Related]
39. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.
Zhang J; Cheng J; Zeng Z; Wang Y; Li X; Xie Q; Jia J; Yan Y; Guo Z; Gao J; Yao M; Chen X; Lu F
Oncotarget; 2015 Dec; 6(39):42040-52. PubMed ID: 26547929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
